Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

It's right there. All you had to do

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
JPG77 Member Profile
 
Followed By 19
Posts 1,729
Boards Moderated 1
Alias Born 05/08/15
160x600 placeholder
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 9/15/2020 5:06:59 PM
Prospectus Filed Pursuant to Rule 424(b)(7) (424b7) Edgar (US Regulatory) - 9/14/2020 4:31:44 PM
SA Breaking News: ALYI - Alternet Systems revenue surging with new potential customers InvestorsHub NewsWire - 9/14/2020 10:10:04 AM
Traders News Source Identifies Tomorrows NASDAQ's InvestorsHub NewsWire - 9/3/2020 8:45:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 9/1/2020 5:34:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/1/2020 2:57:56 PM
Annual Statement of Changes in Beneficial Ownership (5) Edgar (US Regulatory) - 9/1/2020 1:47:41 PM
MICROCAP DAILY - The Exciting Story of Puration Inc (OTCMKTS: PURA) InvestorsHub NewsWire - 8/26/2020 9:02:56 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/18/2020 4:31:34 PM
Annual Report (10-k) Edgar (US Regulatory) - 8/14/2020 5:19:57 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2020 5:21:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2020 4:34:37 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 7/8/2020 5:07:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/8/2020 4:31:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2020 5:19:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 7:24:49 PM
Proxy Soliciting Materials (revised) (prer14a) Edgar (US Regulatory) - 6/8/2020 5:28:53 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 6/8/2020 6:02:50 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/2/2020 5:01:56 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 6/2/2020 8:01:17 AM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 5/15/2020 8:47:08 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/12/2020 6:00:59 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 4/30/2020 5:28:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/28/2020 5:29:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/27/2020 5:03:47 PM
JPG77   Wednesday, 05/06/20 07:59:44 AM
Re: A deleted message
Post # of 119340 
It's right there. All you had to do was look.

"At study day zero, all ten critically ill patients received a subcutaneous 700mg injection of leronlimab following baseline blood collection. Because defining features of severe COVID-19 disease include plasma IL-6 and T cell lymphopenia2,19, and we observed >100-fold increased CCL5 levels compared to normal controls (Fig. 1d), we longitudinally monitored these parameters for two weeks after leronlimab treatment. A reduction of plasma IL-6 was observed as early as three days following leronlimab and returned to healthy control levels by day 14 (Fig. 2a). In contrast, more variable levels were observed with IL-1ß, IL-8, and CCL5 after leronlimab treatment (Supplementary Fig. 2). Following leronlimab administration, a marked restoration of CD8+ T cells (Fig. 2b) and a normalization of the CD4+ and CD8+ T cell ratio in blood was observed (Fig. 2c). These immunological changes occurred concomitant with full leronlimab CCR5 receptor occupancy on the surface of CCR5+ T cells and macrophages (Fig. 2d, 2e). Low levels of SARS-CoV-2 have been detected, but not yet quantified in the plasma of COVID-19 patients19. We used high sensitivity, digital droplet PCR to quantify plasma SARS-CoV-2 viremia at baseline. SARS-CoV-2 was found in the plasma of all ten critically ill patients, underscoring the severity of COVID-19 (Fig. 2f). Following leronlimab administration SARS-CoV-2 plasma viremia decreased in all patients at day seven, suggesting more effective anti-viral immunity following leronlimab-mediated CCR5 blockade."

My comments are just my opinions and should NOT be taken as investment advice.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences